- Antithrombin therapies are essential treatments for coagulation disorders, including antithrombin deficiencies, deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombotic events
- The demand for antithrombin products is significantly driven by the rising prevalence of coagulation disorders and the growing number of surgical procedures where anticoagulation therapies are necessary to prevent thrombotic complications
- North America is expected to dominate the antithrombin, holding approximately 40% share of the total market due to the advanced healthcare infrastructure, widespread adoption of innovative biopharmaceutical technologies, and a strong presence of leading market player
- Asia-Pacific is anticipated to experience the fastest growth in the antithrombin market during the forecast period, owing to increasing awareness of coagulation disorders, improvements in healthcare systems, and the rising burden of thrombotic diseases in countries such as China and India
- Therapeutics segment is expected to dominate the market with a market share of 95% due to its critical role in treating conditions such as hereditary antithrombin deficiency and preventing thromboembolic events during surgeries
